Cetus
Executive Summary
Plans to begin clinicals immediately on a combination of Proleukin (interleukin-2) and tumor necrosis factor (TNF), two therapeutic anticancer agents. Accoring to Cetus, Proleukin and TNF, when used together, may have a synergistic effect in killing a variety of tumors. Preclinical animal studies show the combination to be more effective than either agent alone, firm says.